Credit Suisse Group began coverage on shares of AveXis (NASDAQ:AVXS) in a report released on Wednesday, Marketbeat reports. The brokerage issued an outperform rating and a $134.00 price objective on the stock.
A number of other research firms have also recently issued reports on AVXS. Canaccord Genuity set a $110.00 target price on AveXis and gave the company a hold rating in a research note on Friday, January 5th. Zacks Investment Research raised AveXis from a sell rating to a hold rating in a research note on Tuesday, January 9th. Citigroup boosted their target price on AveXis from $100.00 to $116.00 and gave the company a buy rating in a research note on Monday, October 2nd. Morgan Stanley set a $120.00 target price on AveXis and gave the company a buy rating in a research note on Friday, January 5th. Finally, Chardan Capital reissued a buy rating and issued a $135.00 target price on shares of AveXis in a research note on Friday, January 5th. Three analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. AveXis has an average rating of Buy and a consensus target price of $113.89.
Shares of AveXis (NASDAQ:AVXS) opened at $108.25 on Wednesday. AveXis has a 52 week low of $50.56 and a 52 week high of $119.00.
In other news, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $101.26, for a total transaction of $180,242.80. Following the completion of the transaction, the vice president now directly owns 1,780 shares of the company’s stock, valued at $180,242.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Andrew F. Knudten sold 2,000 shares of the company’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $94.48, for a total value of $188,960.00. Following the transaction, the vice president now directly owns 7,000 shares of the company’s stock, valued at $661,360. The disclosure for this sale can be found here. Insiders have sold 57,340 shares of company stock valued at $5,851,445 over the last ninety days. 18.60% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of AVXS. Strs Ohio acquired a new position in shares of AveXis during the third quarter worth about $116,000. Ameritas Investment Partners Inc. boosted its position in shares of AveXis by 331.0% during the second quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock worth $174,000 after buying an additional 1,622 shares during the period. Cubist Systematic Strategies LLC boosted its position in shares of AveXis by 688.6% during the third quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after buying an additional 1,577 shares during the period. Teacher Retirement System of Texas acquired a new position in shares of AveXis during the third quarter worth about $200,000. Finally, Deschutes Portfolio Strategy LLC acquired a new position in shares of AveXis during the third quarter worth about $203,000. 92.88% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This report was first published by Week Herald and is owned by of Week Herald. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://weekherald.com/2018/01/20/avexis-avxs-earns-outperform-rating-from-analysts-at-credit-suisse-group.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.